The value of Tc-99m-tetrofosmin scintigraphy in the assessment of P-glycoprotein in patients with malignant bone and soft-tissue tumors

Annals of Nuclear Medicine

Volumn 17, Issue 6, 2003, Pages 443-449

  Yapar, Zeynep ^a,c   Kibar, Mustafa ^a   Yapar, A Fuat ^b   Uguz, Aysun ^a   Ozbarlas, Serdar ^a   Gonlusen, Gulfiliz ^a  

^a CUKUROVA UNIVERSITY FACULTY OF MEDICINE   (Turkey)

^b ADANA NUMUNE EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^c CUKUROVA UNIVERSITY   (Turkey)

Author keywords

Malignant bone and soft tissue tumors; P glycoprotein; Tc 99m tetrofosmin

Indexed keywords

GLYCOPROTEIN P; TETROFOSMIN TC 99M;

ADOLESCENT; ADULT; AGED; ARTICLE; BONE CANCER; CANCER RESISTANCE; CLINICAL ARTICLE; DRUG UPTAKE; FEMALE; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SCINTIANGIOGRAPHY; SENSITIVITY AND SPECIFICITY; SOFT TISSUE TUMOR;

EID: 0141644214     PISSN: 09147187     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03006432     Document Type: Article

References (30)

1. Baldini N, Scotlandi K, Barbanti-Brodano G, Manara MC, Maurici D, Bacci G, et al. Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N Engl J Med 1995; 333: 1380-1385.
2. Kostakoglu L. Multidrug Resistance. Part B: Other Tumours. In: Khalkhali I, Maublant JC, Goldsmith SJ, eds. Nuclear Oncology-Diagnosis & Therapy. Philadelphia; Lippincott Williams & Wilkins, 2001: 73-82.
3. Baldini N, Scotlandi K, Serra M, Picci P, Bacci G, Sottili S, et al. P-glycoprotein expression in osteosarcoma: a basis for risk-adapted adjuvant chemotherapy. J Orthop Res 1999; 17: 629-632.
4. Kusuzaki K, Hirata M, Takeshita H, Murata H, Hashiguchi S, Ashihara T, et al. Relationship between P-glycoprotein positivity, doxorubicin binding ability and histologic response to preoperative chemotherapy in osteosarcoma. Cancer Lett 1999; 26: 203-208.
5. Levine EA, Holzmayer T, Bacus S, Mechetner E, Mera I, Bolliger C, et al. Evaluation of newer prognostic markers for adult soft tissue sarcomas. J Clin Oncol 1997; 15: 3249-3257.
6. Chan HS, Thorner PS, Haddad G, Ling V. Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft-tissue sarcoma of childhood. J Clin Oncol 1990; 8: 689-704.
7. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993; 62: 385-427.
8. Kostakoglu L, Uysal U, Özyar E, Demirkazik FB, Hayran M, Atahan L, et al. A comparative study of technetium-99m sestamibi and technetium-99m tetrofosmin single-photon emission tomography in the detection of nasopharyngeal carcinoma. Eur J Nucl Med 1997; 24: 621-628.
9. Obwegeser I, Berghammer P, Rodrigues M, et al. A head-to-head comparison between technetium-99m-tetrofosmin and technetium-99m-MIBI scintigraphy to evaluate suspicious breast lesions. Eur J Nucl Med 1999; 26: 1553-1559.
10. Takekawa H, Shinano H, Tsukamoto E, Koseki Y, Ikeno T, Miller F, et al. Technetium-99m-tetrofosmin imaging of lung cancer: relationship with histopathology. Ann Nucl Med 1999; 13 (2): 71-75.
11. 99mTc-tetrofosmin scintigraphy. Radiot Med 2001; 19 (3): 169-172.
12. 99mTc-tetrofosmin. Nucl Med Commun 1999; 20 (4): 353-359.
13. 99mTc-tetrofosmin scintigraphy in musculoskeletal tumors: the relationship between P-glycoprotein expression and tetrofosmin uptake in malignant lesions. Nucl Med Commun 2002; 23 (10): 991-1000.
14. Soricelli A, Cuocolo A, Varrone A, Discepolo A, Tedeschi E, Mainenti PP, et al. Technetiun-99m-tetrofosmin uptake in brain tumours by SPECT: comparison with thallium-201 imaging. J Nucl Med 1998; 39: 802-806.
15. Arbab AS, Koizumi K, Toyama K, Araki T. Uptake of technetium-99m-tetrofosmin, technetiun-99m-MIBI and thallium-201 in tumour cell lines. J Nucl Med 1996; 37: 1551-1556.
16. Ballinger JR, Bannerman J, Boxen I, Firby P, Hartman NG, Moore MJ. Technetium-99m-tetrofosmin as a substrate for P-glycoprotein: in vitro studies in multidrug-resistant breast tumour cells. J Nucl Med 1996; 37 (9): 1578-1582.
17. Perek N, Prevot N, Koumanov F, Frere D, Sabido O, Beauchesne P. Involvement of the glutathione S-conjugate compounds and the MRP protein in Tc-99m-tetrofosmin and Tc-99m-sestamibi uptake glioma cell lines. Nucl Med Biol 2000; 27 (3): 299-307.
18. Muzzammil T, Moore MJ, Ballinger JR. In vitro comparison of sestamibi, tetrofosmin, and furifosmin as agents for functional imaging of multidrug resistance in tumours. Cancer Biother Radiopharm 2000; 15 (4): 339-346.
19. Utsunomiya K, Ballinger JR, Piquette-Miller M, Rauth AM, Tang W, Su ZF. Comparison of the accumulation and efflux kinetics of technetium-99m sestamibi and technetium-99m tetrofosmin in an MRP-expressing tumour cell line. Eur J Nucl Med 2000; 27: 1786-1792.
20. Waxman AD, Abdel-Dayem HM. Primary Bone Tumors: Thallium-201, Technetium-99m-sestamibi, and Fluorine-18-deoxyglucose. In: Kbalkhali I, Maublant JC, Goldsmith SJ, eds. Nuclear Oncology-Diagnosis & Therapy. Philadelphia; Lippincott Williams & Wilkins, 2001: 509-524.
21. Higley B, Smith FW, Smith T, Gemmell HG, Das Gupta P, Gvozdanovic DV, et al. Technetium-99m-1,2-bis [bis (2-ethoxyethyl) phosphino] ethane: human biodistribution, dosimetry and safety of a new myocardial perfusion imaging agent. J Nucl Med 1993; 34: 30-38.
22. Rossetti C, Vanoli G, Paganelli G, Kwiatkowski M, Zito F, Colombo F, et al. Human biodistribution, dosimetry and clinical use of technetium(III)-99m-Q 12. J Nucl Med 1994; 35: 1571-1580.
23. 99mTc-furifosmin uptake in human soft tissue sarcoma cell lines. Eur J Nucl Med 2000; 27: 1839-1843.
24. Crankshaw C, Marmion M, Luker G, Rao V, Dahlheimer J, Burleigh BD, et al. Novel Tc(III)-Q-complexes for functional imaging of the multidrug resistance (MDR1) P-glycoprotein. J Nucl Med 1998; 39: 77-86.
25. 99mTc-tetrofosmin chest imaging. J Nucl Med 2002; 42: 17-20.
26. Shiau YC, Tsai SC, Wang JJ, Ho YJ, Ho ST, Kao CH. Predicting chemotherapy response and comparing with P-glycoprotein expression using technetium-99m tetrofosmin scan in untreated malignant lymphomas. Cancer Lett 2001; 170: 139-146.
27. Liu TJ, Tsai SC, Ho YJ, Sun SS, Kao CH. Comparison of the expression of P-glycoprotein Ki-67, and P-53 to technetium-99m tetrofosmin mammoscintigraphic findings. Cancer Invest 2002; 20 (2): 199-205.
28. Taki J, Sumiya H, Asada N, Ueda Y, Tsuchiya H, Tonami N. Assessment of P-glycoprotein in patients with malignant bone and soft-tissue tumors using technetium-99m-MIBI scintigraphy. J Nucl Med 1998; 39: 1179-1184.
29. 99mTc-MIBI scintigraphy in the assessment of MDR1 overexpression in patients with musculoskeletal sarcomas: comparison with therapy response. Eur J Nucl Med 2001; 28: 1341-1350.
30. Shiau YC, Tsai SC, Wang JJ, Ho YJ, Ho ST, Kao CH. To predict chemotherapy response using technetium-99m tetrofosmin and compare with p-glycoprotein and multidrug resistance related protein-1 expression in patients with untreated small cell lung cancer. Cancer Lett 2001; 169: 181-188.